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LETTERS
Arcanobacterium 
pyogenes Sepsis  
in Farmer, Brazil
To the Editor: Arcanobacterium 
pyogenes  is  a  normal  inhabitant  of 
the  mucous  membranes  of  domestic 
animals, such as cattle, sheep, swine, 
and goats (1). Diseases caused by this 
agent have been reported for persons 
who live in rural areas and have un-
derlying illnesses such as cancer and 
diabetes  (2–4).  A  recent  literature 
review  (3),  elicited  by  a  case  of  A. 
pyogenes endocarditis, found 13 un-
equivocal  cases  of  human  infection 
with this agent; many patients had a 
history of close contact with domestic 
animals. However, septicemia was not 
reported. 
In June 2006, a 27-year-old im-
munocompetent  man  was  hospital-
ized in Campinas (São Paulo, Brazil) 
for fever, cough with purulent bloody 
sputum, and discharge from and pain 
in both ears. The patient was a farmer 
who lived in the rural Amazon area 
and had extensive contact with cattle 
and  swine.  For  the  past  3  days  he 
had  been  taking  amoxicillin,  1.5  g/
day, for chronic otitis media. At the 
time of hospital admission, his tem-
perature was 38.9°C, respiratory rate 
24  breaths/min,  and  blood  pressure 
100/70 mm Hg. He had palpable hepa-
tosplenomegaly, but no murmur was 
detected in the precordium. Computed 
tomography  (CT)  scan  of  his  chest 
showed  multiple  pulmonary  nodules 
and alveolar infiltrates with small cav-
ities suggestive of septic infarctions. 
Abdominal CT scan confirmed hepa-
tosplenomegaly with focal lesions in 
the spleen. CT scan of the middle ear 
showed  bilateral  cholesteatoma  and 
mastoiditis.  No  abnormalities  were 
found during 2 transthoracic echocar-
diography  procedures.  Laboratory 
values were PaO2 63.4 mm Hg, hemo-
globin 11.9 g/dL, thrombocytes 109 × 
103/mm3, leukocytes 11.05 × 103/mm3 
with  a  left  shift,  serum  albumin  2.6   
g/dL,  alanine  aminotransferase  108 
U/L, and total bilirubin 2.57 mg/dL. 
Blood and the ear secretion were sub-
mitted for culture. Cefepime was pre-
scribed, 2 g/twice a day.
Three blood cultures grew gram-
positive  bacilli,  initially  identified 
as  Corynebacterium  spp.,  sensitive 
to  penicillin,  ampicillin,  ceftriaxone, 
gentamicin, clindamycin, vancomycin, 
and resistant to erythromycin, as deter-
mined by disk-diffusion test. Ear dis-
charge culture grew Proteus mirabilis, 
sensitive to β-lactams, cephalosporins, 
and  aminoglycosides.  Subcultures 
of the gram-positive bacilli on sheep 
blood agar grew pinpointed, grayish, 
β-hemolytic colonies, identified as A. 
pyogenes by use of API Coryne 2.0 
kit (bioMérieux, Durham, NC, USA; 
code 4732761). Although susceptibil-
ity standards are not available for this 
organism,  it  was  considered  suscep-
tible  to  penicillin  and  ampicillin  by 
combining the disk-diffusion test with 
the MICs, as determined by the Etest 
(0.06 mg/L for penicillin, 0.023 mg/L 
for ampicillin).
Partial 16S rDNA was amplified 
by using primers p27f and BAC1401r 
and  sequenced  by  using  primers 
1100r,  765fs,  and  10f.  Sequences 
were compared with those available in 
GenBank by using gapped BLASTN 
2.0.5  software  (5).  Identification  to 
the  species  level  was  defined  as  a 
16S  rDNA  sequence  identity  >97%. 
Phylogenetic analysis was performed 
by using MEGA version 4.0 (6) after 
multiple alignments of data by Clust-
alX (7); gaps were treated as missing 
data. Clustering was performed by the 
neighbor-joining  method  (8).  Boot-
strap analysis was used to evaluate tree 
topology of the neighbor-joining data 
by performing 1,000 resamplings (9). 
BLASTN analysis of the 16S sequence 
of  the  isolate  showed  99%  identity 
with the 16S sequence of A. pyogenes 
(accession no. X79225). Phylogenetic 
analyses with MEGA grouped this iso-
late with A. pyogenes NCTC 5224 in 
a branch separated from other species; 
this grouping supported the phenotyp-
ic identification.
During  the  7  days  after  admis-
sion, the patient’s condition worsened, 
cefepime  was  withdrawn,  and  am-
picillin 6 g/day plus gentamicin 240 
mg/day were prescribed. The patient 
became afebrile, gradually recovered, 
and was discharged after 28 days of 
therapy.
Our patient had otitis media that 
progressed  to  sepsis,  which  was  di-
agnosed  by  clinical,  laboratory,  and 
imaging findings. The causative agent 
may  have  been  undetectable  in  ear 
discharge if it was overshadowed by 
a  strain  of  P.  mirabilis,  a  fastidious 
organism that also colonizes or co-in-
fects this site. Endocarditis could not 
be ruled out because transesophageal 
echocardiography was not available.
A.  pyogenes  is  usually  suscep-
tible to benzyl penicillin, ampicillin, 
gentamicin,  and  macrolides  and  re-
sistant  to  trimethoprim/sulfamethox-
azole, streptomycin, and tetracyclines 
(10). The isolate from this patient was 
sensitive  to  β-lactams,  ceftriaxone, 
and  gentamicin.  However,  suscepti-
bility standards are not available be-
cause A. pyogenes rarely causes dis-
ease in humans. The patient had taken 
oral  amoxicillin  before  admission, 
but his condition had not improved; 
subsequent addition of cefepime was 
also unsuccessful. The organism was 
probably sensitive to ampicillin, con-
sidering the low MIC and the expect-
ed serum concentration of the drug, 
but diffusion into the middle ear may 
have been poor or the local conditions 
caused by the cholesteatoma may have 
influenced the poor outcome of initial 
therapy.  Treatment  with  intravenous 
ampicillin plus gentamicin produced 
full recovery.
Clinical  laboratories  do  not  rou-
tinely attempt to identify this organism. 
However, even in the absence of sub-
stantial concurrent illness, A. pyogenes 
must  be  considered  as  an  etiologic 
agent of several human infections, es-
pecially septicemia, for patients with a 
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history of close contact with domestic 
animals, mainly cattle and swine.
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Reactivation of  
Bovine Tuberculosis   
in Patient Treated 
with Infliximab, 
Switzerland
To  the  Editor:  Increased  risk 
for reactivation of tuberculosis (TB) 
after  treatment  with  tumor  necrosis 
factor (TNF) antagonists, particularly 
infliximab,  is  well  documented  (1). 
We describe a case of peritoneal TB, 
probably  resulting  from  reactivation 
of Mycobacterium bovis infection af-
ter infliximab treatment. In retrospect, 
reactivation might have been prevent-
able had physicians been aware of the 
patient’s history of regularly drinking 
fresh cow’s milk from a local farm in 
Switzerland  during  1944–45,  when 
bovine TB was prevalent.
The  patient  was  a  69-year-old 
Swiss woman who was examined for 
weakness,  abdominal  pain,  increas-
ing abdominal girth, and weight loss 
in April 2008. Her history included a 
diagnosis  of  Crohn  disease  in  1978 
and  treatment  with  glucocorticoids, 
cyclosporine,  and  mercaptopurine. 
In  November  2007,  during  a  recur-
rence of Crohn disease and while re-
ceiving  treatment  with  azathioprine, 
the patient had a negative interferon 
gamma  release  assay  (IGRA)  result 
(QuantiFERON-TB in Tube test; Cell-
estis International, Carnegie, Victoria, 
Australia) and an unremarkable chest 
radiograph. On November 30, 2007, 
she  was  given  prednisone  (40  mg/d 
for  2  weeks,  then  tapered)  and  pre-
scribed 3 doses of infliximab because 
of  severe  inflammation  seen  during 
colonoscopy (5 mg/kg on November 
30, 2007, January 4, 2008, and Febru-
ary 15, 2008). She was hospitalized on 
April 25, 2008, at which time she had 
ascites; the fluid contained 1.4 × 109/L 
leukocytes  (79.5%  lymphocytes)  but 
was negative for acid-fast bacilli on 
direct examination and PCR testing for 
Mycobacterium tuberculosis complex. 
Laparoscopy on May 2, 2008, showed 
extensive  peritoneal  inflammation. 
Peritoneal  biopsy  samples  contained 
acid-fast bacilli and caseating granu-
lomas; PCR for M. tuberculosis com-
plex was positive. At this time, results 
of a repeat QuantiFERON-TB in Tube 
test and a tuberculin skin test (TST) 
were negative, but a T-SPOT.TB (Ox-
ford Immunotec, Abingdon, UK) test 
was  positive  (6-kDa  early  secretory 
antigenic target [ESAT-6], >20 spots; 
10-kDa culture filtrate protein [CFP-
10], 11 spots). M. bovis ssp. bovis was 
grown in cultures of peritoneal biopsy 
samples. For culture, the MGIT 960 
automated  culture  system  (Becton 
Dickinson,  Sparks,  MD,  USA)  was 
used.  The  isolate  was  identified  by 
use of a multiplex PCR-based, solid-
phase,  reverse-hybridization  assay 
(GenoType MTBC, Hain Lifescience 
GmbH, Nehren, Germany), excluding 
M.  bovis  BCG  (2). The  patient  was 
discharged May 30, 2008. In January 
2009,  she  was  much  improved  after 
treatment  with  isoniazid/rifampin/
ethambutol  for  3  months  and  moxi-
floxacin/rifampin for 5 months.
This case of presumed reactiva-
tion of peritoneal TB caused by M. 
bovis in a patient treated with inflix-
imab highlights the need to be aware 
of  local  epidemiology  with  regard 
to  transmissible  infectious  diseases. 
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